Prostate Cancer - Results from #660

Risk of cardiovascular thrombotic events after surgical castration versus gonadotropin-releasing hormone agonists in Chinese men with prostate cancer, "Beyond the Abstract," by Jeremy Y.C. Teoh and Anthony C.F. Ng June 1, 2015

Survival outcomes of Chinese metastatic prostate cancer patients following primary androgen deprivation therapy in relation to prostate-specific antigen nadir level, "Beyond the Abstract," by Jeremy Y.C. Teoh and Ming-Kwong Yiu May 29, 2015

A sector-based dosimetric analysis of dose heterogeneity in high-dose-rate prostate brachytherapy, "Beyond the Abstract," by Shane Mesko, BS and Mitchell Kamrava, MD May 29, 2015

Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone, "Beyond the Abstract," by Ugo De Giorgi May 28, 2015

Complications following artificial urinary sphincter placement after radical prostatectomy and radiotherapy, "Beyond the Abstract," by Anthony S. Bates and Tim R. Terry May 28, 2015

Differential requirement for Src-family tyrosine kinases in the initiation, progression and metastasis of prostate cancer, "Beyond the Abstract," by Irwin H. Gelman, PhD May 27, 2015

A dosimetric comparison of volumetric modulated arc therapy with step-and-shoot intensity modulated radiation therapy for prostate cancer, "Beyond the Abstract," by Richard Wilder, MD, MS, MBA May 27, 2015

Detection and phenotyping of circulating tumor cells in high-risk localized prostate cancer, "Beyond the Abstract," by Jeremy Jones, PhD May 26, 2015

A comprehensive review of contemporary role of local treatment of the primary tumor and/or the metastases in metastatic prostate cancer, "Beyond the Abstract," by Fouad Aoun, MD, MSc May 26, 2015

A validation study of the cutoff level of free/total prostate specific antigen (f/t PSA) ratios in the diagnosis of prostate cancer in a Turkish patient population in different age categories, "Beyond the Abstract," by Bulent Erol, MD May 14, 2015

Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance), "Beyond the Abstract," by Jai N. Patel, PharmD May 12, 2015

A phase II trial of stereotactic ablative body radiotherapy for low-risk prostate cancer using a non-robotic linear accelerator and real-time target tracking, "Beyond the Abstract," by Constantine A. Mantz, MD May 12, 2015

Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for prostate cancer, "Beyond the Abstract," by Danny Monther Rabah May 8, 2015

Prostate volume predicts high grade prostate cancer both in digital rectal examination negative (ct1c) and positive (≥ct2) patients, "Beyond the Abstract," by Murat Üstüner, MD May 7, 2015

Prostate cancer screening is associated with educational level and knowledge about the disease, "Beyond the Abstract," by Camilo Novoa Brunet May 5, 2015

Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer, "Beyond the Abstract," by Elena Castro, MD, PhD May 4, 2015

Reclassification rates are higher among African American men than Caucasians on active surveillance, "Beyond the Abstract," by Debasish Sundi, MD and Edward M. Schaeffer, MD, PhD May 1, 2015

Multiparametric magnetic resonance imaging localizes established extracapsular extension of prostate cancer, "Beyond the Abstract," by Tom S. Feng, MD May 1, 2015

A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer, "Beyond the Abstract," by Neha Vapiwala, MD April 29, 2015

Integrated analysis of epigenomic and genomic changes by DNA methylation dependent mechanisms provides potential novel biomarkers for prostate cancer, "Beyond the Abstract," by Nicole White-Al Habeeb and Bharati Bapat April 28, 2015

Page 34 of 58